Alimatravir clinical trials
Also written MK-8527.
How each study uses alimatravir is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the alimatravir studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
17 studies that test it; most in 2025 (8)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
| 2025 | 8 |
| 2026 | 4 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 17 · Other 0
Often tested with
Tested in the same studies.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Reaching primary completion within a year · 3, 2 in phase 3
Studies that test alimatravir, phase 3 first.
- Jul 2027A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)Phase 3 · Merck Sharp & Dohme LLC
- Oct 2027A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)Phase 3 · Merck Sharp & Dohme LLC
- Jan 2027A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)Phase 1 · Merck Sharp & Dohme LLC
Studies
Open first, then newest update. How each study uses alimatravir is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- A Clinical Study of Alimatravir (MK-8527) in Transgender (Trans) and Gender Diverse Individuals on Gender-affirming Hormone Therapy and at Low Likelihood of Human Immunodeficiency Virus (HIV)-1 Exposure (MK-8527-018)RecruitingPhase 2Merck Sharp & Dohme LLCNCT07850609Written as Alimatravir
- A Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-010)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07071623Written as MK-8527
- A Clinical Trial of MK-8527 and Rifampin in Adult Participants With Latent Tuberculosis Infection (MK-8527-019)Not yet recruitingPhase 1Merck Sharp & Dohme LLCNCT07600775Written as MK-8527
- A Clinical Study of MK-8527 in Healthy Participants (MK-8527-021)CompletedPhase 1Merck Sharp & Dohme LLCNCT07661108Written as MK-8527
- A Clinical Study of MK-8527 to Prevent Human Immunodeficiency Virus Type 1 (HIV-1) (MK-8527-011)Active, not recruitingPhase 3Merck Sharp & Dohme LLCNCT07044297Written as MK-8527
- A Clinical Trial in Healthy Participants to Study the Effect of a Single Dose of MK-8527 on Levels of Methadone (MK-8527-020)CompletedPhase 1Merck Sharp & Dohme LLCNCT07528508Written as MK-8527
- A Study of MK-8527 in Healthy Lactating Female Participants (MK-8527-009)CompletedPhase 1Merck Sharp & Dohme LLCNCT06580587Written as MK-8527
- A Clinical Study of MK-8527 in Participants With Mild and Moderate Hepatic Impairment (MK-8527-015)CompletedPhase 1Merck Sharp & Dohme LLCNCT07025551Written as MK-8527
- A Study of MK-8527 in Participants With Moderate and Severe Renal Impairment (MK-8527-008)CompletedPhase 1Merck Sharp & Dohme LLCNCT06295796Written as MK-8527
- A Clinical Study of MK-8527 in Healthy Adult Participants (MK-8527-014)CompletedPhase 1Merck Sharp & Dohme LLCNCT07063238Written as MK-8527
- Safety and Pharmacokinetic Study of Oral MK-8527 QM in Participants at Low-Risk for HIV-1 Infection (MK-8527-007)CompletedPhase 2Merck Sharp & Dohme LLCNCT06045507Written as MK-8527
- A Study of Carbamazepine (CBZ) and MK-8527 in Healthy Adult Participants (MK-8527-012)CompletedPhase 1Merck Sharp & Dohme LLCNCT06893081Written as MK-8527
- A Study of Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) and MK-8527 in Healthy ParticipantsCompletedPhase 1Merck Sharp & Dohme LLCNCT06816043Written as MK-8527
- A Study of MK-8527 in Healthy Adult Participants (MK-8527-013)CompletedPhase 1Merck Sharp & Dohme LLCNCT06826989Written as [14C]MK-8527
- MK-8527 Single-Dose Trial in HIV-1 Infected Participants (MK-8527-004)CompletedPhase 1Merck Sharp & Dohme LLCNCT05494736Written as MK-8527
- A Drug-Drug Interaction Study of MK 8527 With a Combined Oral Contraceptive (LNG/EE)CompletedPhase 1Merck Sharp & Dohme LLCNCT06783192Written as MK-8527
- A Study of MK-8527 in Human Immunodeficiency Type 1 Virus (HIV-1) Infected Participants (MK-8527-002)CompletedPhase 1Merck Sharp & Dohme LLCNCT03615183Written as MK-8527
What changed recently
From the registry's own updates since Oct 18, 2026.
Codes
What other systems call alimatravir · ClinicalTrials.gg INT016620
- UNII (FDA) G2CS3JB82TALIMATRAVIROne source FDA
- NCI Thesaurus C224709AlimatravirOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | G2CS3JB82T | ALIMATRAVIR | One source FDA |
| NCI Thesaurus | C224709 | Alimatravir | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.